Evidence map›Paper›PMID 35458549›Full record

ArticleViruses2022

Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2.

Mai Izumida, Osamu Kotani, Hideki Hayashi, Chris Smith, Tsutomu Fukuda, Koushirou Suga, Masatomo Iwao, Fumito Ishibashi, Hironori Sato, Yoshinao Kubo

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Dextran sulfate fromFrontiers in microbiology · 2023
    Article
  7. Viruses · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Mai IzumidaDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.
Osamu KotaniPathogen Genomics Center, National Institute for Infectious Diseases, Tokyo 208-0011, Japan.
Hideki HayashiMedical University Research Administrator, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan.ORCID 0000-0003-4585-6542
Chris SmithDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0000-0001-9238-3202
Tsutomu FukudaEnvironmental Protection Center, Nagasaki University, Nagasaki 852-8131, Japan.ORCID 0000-0002-5400-2808
Koushirou SugaGraduate School of Fisheries and Environmental Sciences, Nagasaki University, Nagasaki 852-8131, Japan.
Masatomo IwaoGraduate School of Engineering, Nagasaki University, Nagasaki 852-8131, Japan.
Fumito IshibashiGraduate School of Fisheries and Environmental Sciences, Nagasaki University, Nagasaki 852-8131, Japan.
Hironori SatoPathogen Genomics Center, National Institute for Infectious Diseases, Tokyo 208-0011, Japan.
Yoshinao KuboDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0000-0001-6592-8035
Nagasaki University · JPNational Institute of Infectious Diseases · JPUniversity of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lamellarin α 20-sulfate is a cell-impenetrable marine alkaloid that can suppress infection that is mediated by the envelope glycoprotein of human immunodeficiency virus type 1. We explored the antiviral action and mechanisms of this alkaloid against emerging enveloped RNA viruses that use endocytosis for infection. The alkaloid inhibited the infection of retroviral vectors that had been pseudotyped with the envelope glycoprotein of Ebola virus and SARS-CoV-2. The antiviral effects of lamellarin were independent of the retrovirus Gag-Pol proteins. Interestingly, although heparin and dextran sulfate suppressed the cell attachment of vector particles, lamellarin did not. In silico structural analyses of the trimeric glycoprotein of the Ebola virus disclosed that the principal lamellarin-binding site is confined to a previously unappreciated cavity near the NPC1-binding site and fusion loop, whereas those for heparin and dextran sulfate were dispersed across the attachment and fusion subunits of the glycoproteins. Notably, lamellarin binding to this cavity was augmented under conditions where the pH was 5.0. These results suggest that the final action of the alkaloid against Ebola virus is specific to events following endocytosis, possibly during conformational glycoprotein changes in the acidic environment of endosomes. Our findings highlight the unique biological and physicochemical features of lamellarin α 20-sulfate and should lead to the further use of broadly reactive antivirals to explore the structural mechanisms of virus replication.

Indexed as

AlkaloidsCOVID-19 Drug TreatmentEbolavirusHemorrhagic Fever, EbolaAntiviral AgentsDextran SulfateGlycoproteinsHeparinHumansSARS-CoV-2Virus InternalizationAlkaloidsAntiviral AgentsDextran SulfateGlycoproteinsHeparinantiviral actionantiviral mechanismdocking simulationemerging viruseslamellarin α 20-sulfatemarine alkaloidmolecular dynamics simulationpseudotyped lentiviral vector

Identifiers

PMID35458549
PMCPMC9028129
OpenAlexW4224263376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.